Phase 2
Development Phase
0
Upcoming Catalysts
0
Historical Events
0
Regulatory Approvals
No catalyst events have been recorded for this drug yet.
Target Indication
Neovascular Age-related Macular Degeneration
Clinical Trial
NCT04626128Last updated: 12/4/2025
CLSD
Clearside Biomedical, Inc.
